Moderna 和 Vertex 建立新的合作,通过基因编辑治疗囊性纤维化

路透社 · 2020-09-17
EN to CN

Sept 16 (Reuters) - Moderna Inc (MRNA.O) :

  • MODERNA AND VERTEX ESTABLISH NEW COLLABORATION TO TREAT CYSTIC FIBROSIS USING GENE EDITING

  • MODERNA INC - SECOND COLLABORATION BETWEEN MODERNA AND VERTEX BASED ON MODERNA’S PROPRIETARY MRNA AND LNP TECHNOLOGY

  • MODERNA INC - MODERNA TO RECEIVE $75 MILLION UPFRONT, WITH POTENTIAL FOR ADDITIONAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES AND ROYALTY PAYMENTS

  • MODERNA INC - ELIGIBLE TO RECEIVE UP TO $380 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES, PLUS ROYALTIES FROM COLLABORATION WITH VERTEX

  • MODERNA - THREE-YEAR RESEARCH COLLABORATION WITH VERTEX INITIALLY TO FOCUS ON DISCOVERY AND OPTIMIZATION OF NOVEL LNPS AND MRNAS

Long Bridge Securities Ltd is a New Zealand registered Financial Service Provider (FSP number: FSP600050), and is a member of the Financial Dispute Resolution Scheme, a New Zealand independent dispute resolution service provider.

All data and contents of the Long Bridge website (longbridge.global) are for investors' reference only. Before conducting investment activities, investors should fully understand the relevant products, clearly know their potential risks, and make rational decisions based on their own risk tolerance; and investors should be aware that all investment activities involve risks and investment activities may not be suitable for every investor.

Customer Service (Only for general enquiries):400-071-2688

0800 33 9033 / (09) 533 9033(New Zealand)

Support Email: service@longbridge.global
简体中文